Research programme: chronic obstructive pulmonary disease therapeutics - Medivir
Latest Information Update: 16 Jul 2016
At a glance
- Originator Medivir AB
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Sweden
- 28 Nov 2007 Preclinical trials in Chronic obstructive pulmonary disease in Sweden (unspecified route)